genetics · Mechanism Report

Does the rs7412 C allele exclude the APOE ε2 isoform?

Carrying a C allele at rs7412 on a chromosome prevents that chromosome from encoding the APOE ε2 isoform.

PlausibleJuly 1, 202611 Sources

This is what AI claimed

APOE rs7412 is one of the two key SNPs that determine APOE ε2/ε3/ε4 isoforms, and the rs7412 C allele corresponds to the absence of ε2.

3 of 5 paths supported

Executive summary

The claim states that APOE isoforms ε2/ε3/ε4 are determined by the combination of rs7412 and rs429358 alleles, and that ε2 specifically requires a T at rs7412. The mechanism graph and conclusion frame rs7412-C as genetically incompatible with ε2 and note functional consequences tied to the differing amino acid (Arg158 vs Cys158) that affect receptor binding and downstream clinical phenotypes.

Verified conclusion

The canonical apolipoprotein E (APOE) isoforms—ε2, ε3, and ε4—are dictated by a specific di-genic haplotype on exon 4 of the APOE gene.

Genetic architecture and isoform determination

Dual-SNP Haplotype: The major isoforms are determined by the combination of alleles at two single nucleotide polymorphisms (SNPs): rs429358 (codon 112) and rs7412 (codon 158).
Exclusion of ε2: The ε2 haplotype is defined by rs429358-T (Cys112) and rs7412-T (Cys158). Because the ε2 isoform strictly requires a T allele at rs7412, the presence of a C allele at this locus (encoding Arg158) definitively rules out the ε2 haplotype on that chromosome. Individuals with an rs7412-CC genotype completely lack the ε2 allele.

Mechanistic and structural implications

Receptor Binding Affinity: The rs7412 T allele (Cys158) in the ε2 isoform substantially reduces its binding affinity to the low-density lipoprotein (LDL) receptor. Conversely, the C allele (Arg158) maintains normal, high-affinity receptor-binding activity.
Conformational Dynamics: At the other locus, the rs429358 C allele (Arg112) promotes a stronger domain interaction between the N- and C-terminal domains of the APOE protein, driving conformational changes and a preference for very-low-density lipoproteins (VLDL).

Clinical implications

Cardiovascular and Cognitive Profiles: Lacking the ε2 allele (as seen in rs7412-CC homozygotes) deprives individuals of its associated protection against late-onset Alzheimer's disease and its characteristically lower baseline LDL-cholesterol levels.
Statin Response: Non-carriers of the ε2 allele (rs7412-CC) also display distinct pharmacogenetic traits, such as a slightly reduced LDL-cholesterol–lowering response to statin therapy compared to ε2 carriers.

Bottom line

The claim is fully supported: rs7412 and rs429358 jointly determine the functional APOE ε2/ε3/ε4 isoforms, and carrying an rs7412 C allele genetically precludes the existence of the protective ε2 isoform on that chromosome.

References

See a full patient report verified like this

Book a walkthrough

Executive summary

Verified conclusion

The canonical apolipoprotein E (APOE) isoforms—ε2, ε3, and ε4—are dictated by a specific di-genic haplotype on exon 4 of the APOE gene.

Genetic architecture and isoform determination

Dual-SNP Haplotype: The major isoforms are determined by the combination of alleles at two single nucleotide polymorphisms (SNPs): rs429358 (codon 112) and rs7412 (codon 158).
Exclusion of ε2: The ε2 haplotype is defined by rs429358-T (Cys112) and rs7412-T (Cys158). Because the ε2 isoform strictly requires a T allele at rs7412, the presence of a C allele at this locus (encoding Arg158) definitively rules out the ε2 haplotype on that chromosome. Individuals with an rs7412-CC genotype completely lack the ε2 allele.

Mechanistic and structural implications

Receptor Binding Affinity: The rs7412 T allele (Cys158) in the ε2 isoform substantially reduces its binding affinity to the low-density lipoprotein (LDL) receptor. Conversely, the C allele (Arg158) maintains normal, high-affinity receptor-binding activity.
Conformational Dynamics: At the other locus, the rs429358 C allele (Arg112) promotes a stronger domain interaction between the N- and C-terminal domains of the APOE protein, driving conformational changes and a preference for very-low-density lipoproteins (VLDL).

Clinical implications

Cardiovascular and Cognitive Profiles: Lacking the ε2 allele (as seen in rs7412-CC homozygotes) deprives individuals of its associated protection against late-onset Alzheimer's disease and its characteristically lower baseline LDL-cholesterol levels.
Statin Response: Non-carriers of the ε2 allele (rs7412-CC) also display distinct pharmacogenetic traits, such as a slightly reduced LDL-cholesterol–lowering response to statin therapy compared to ε2 carriers.

Bottom line

The claim is fully supported: rs7412 and rs429358 jointly determine the functional APOE ε2/ε3/ε4 isoforms, and carrying an rs7412 C allele genetically precludes the existence of the protective ε2 isoform on that chromosome.